Simos has always been a friend to the company, supporting it when all others abandoned it. Unlike some of the analysts he always asked questions with deference and seemingly to allow the management team to touch upon the high spots during the years I have followed the company.

That said all of the pharma analysts have an agenda. I guess Simos sees some upside to the stock. It would be interesting to see how he has suggested his organizations should be trading MNKD.